Trends in noncardiovascular comorbidities among patients hospitalized for heart failure, Circ Heart Fail, vol.11, p.4646, 2018. ,
Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation, vol.132, pp.923-931, 2015. ,
ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American Heart Association task force on practice guidelines, Circulation, vol.128, pp.1810-1852, 2013. ,
Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial, Diabetes Care, vol.40, pp.1763-1770, 2017. ,
Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial, Diabetes Care, vol.39, pp.1267-1273, 2016. ,
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, vol.379, pp.633-644, 2018. ,
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, vol.373, pp.2125-2135, 2009. ,
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial, Lancet, vol.366, pp.1279-1289, 2005. ,
Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus, JACC Heart Fail, vol.6, pp.813-822, 2018. ,
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, vol.373, pp.2117-2128, 2015. ,
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME â trial, Eur Heart J, vol.37, pp.1526-1534, 2016. ,
Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, vol.377, pp.644-657, 2017. ,
Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, vol.380, pp.1881-1882, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02543624
Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the, American Heart Association. Circulation, vol.135, pp.1054-1091, 2017. ,
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, pp.620-626, 2011. ,
Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, pp.1327-1335, 2013. ,
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.385, pp.2067-2076, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01745763
Early and chronic dipeptidyl-peptidase-IV inhibition and cardiovascular events in patients with type 2 diabetes mellitus after an acute coronary syndrome: a landmark analysis of the EXAMINE trial, J Am Heart Assoc, vol.7, 2018. ,
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial, Diabetes Obes Metab, vol.20, pp.654-659, 2018. ,
Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial, Diabetes Care, vol.41, pp.1510-1515, 2018. ,
Serial measurement of highsensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the examine trial (examination of cardiovascular outcomes with alogliptin versus standard of care), Circulation, vol.135, pp.1911-1921, 2017. ,
Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial, Diabetes Obes Metab, vol.19, pp.962-969, 2017. ,
High sensitivity cardiac troponin assays in the clinical laboratories, Clin Chem Lab Med, vol.53, pp.635-652, 2015. ,
Circulating concentrations of growthdifferentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay, Clin Chem, vol.53, pp.284-291, 2007. ,
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care, Eur Heart J, vol.33, pp.2001-2006, 2012. ,
Reassessing the role of surrogate end points in drug development for heart failure, Circulation, vol.138, pp.1039-1053, 2018. ,
Re-examination of the best trial using composite outcomes, including emergency department visits, JACC Heart Fail, vol.5, pp.591-599, 2017. ,
Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk in Communities (ARIC) study, Diabetes Care, vol.39, pp.677-685, 2016. ,
Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study, JACC Heart Fail, vol.5, pp.724-734, 2017. ,
The transforming growth factor-b superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury, Circ Res, vol.98, pp.351-360, 2006. ,
Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications, J Am Coll Cardiol, vol.56, pp.1071-1078, 2010. ,
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section, Eur Heart J, vol.33, pp.2265-2271, 2012. ,
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, vol.110, pp.3121-3128, 2004. ,
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure, Clin Res Cardiol, vol.102, pp.103-110, 2013. ,
, Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis, Lancet Diabetes Endocrinol, vol.4, pp.840-849, 2016.
Relationship between body mass index, antidiabetic agents, and midterm mortality in patients with both type 2 diabetes mellitus and acute coronary syndrome, J Am Heart Assoc, vol.8, 2019. ,
Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure, J Am Heart Assoc, vol.6, p.5539, 2017. ,
Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease, J Am Heart Assoc, vol.6, 2017. ,
Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction, Diabetes Care, vol.41, pp.1285-1291, 2018. ,
Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes, J Am Coll Cardiol, vol.71, pp.1379-1390, 2018. ,